PBA
KYTX icon

Paradigm Biocapital Advisors’s Kyverna Therapeutics KYTX Stock Holding History

Paradigm Biocapital Advisors’s Portfolio KYTX Stock Details KYTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-50,000
Closed -$1.24M – 43
2024
Q1 		$1.24M Buy
+50,000
New +$1.4M 0.04% 34

Other funds holding KYTX

VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
NV
Northpond Ventures Bethesda, Maryland $43.7M AUM 27.27% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Paradigm Biocapital Advisors's KYTX Position: Q2 2024 in Review

Paradigm Biocapital Advisors sold out of Kyverna Therapeutics (KYTX) in Q2 2024, closing a stake of 50,000 shares — an estimated $1.24M sold.

Paradigm Biocapital Advisors first reported a position in KYTX in Q1 2024 and held it in 1 quarter. The position peaked at $1.24M in Q1 2024. 88 funds tracked by Wall St. Rank hold KYTX as of Q2 2024.

  • Paradigm Biocapital Advisors reported no remaining Kyverna Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 50,000 Kyverna Therapeutics shares in Q2 2024, an estimated $1.24M.
  • Paradigm Biocapital Advisors first reported a position in Kyverna Therapeutics in Q1 2024 and held it in 1 quarter.
  • Paradigm Biocapital Advisors's Kyverna Therapeutics position peaked at $1.24M in Q1 2024.
  • 88 funds tracked by Wall St. Rank held Kyverna Therapeutics as of Q2 2024.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.